ArticleBMC cancer2026
Interpretable machine learning using CT radiomics predicts pathological upgrading after secondary resection in non-muscle-invasive bladder cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
background and purposeRepeat transurethral resection (ReTUR) is essential for reducing residual and recurrent non-muscle-invasive bladder cancer (NMIBC). Pathological upstaging after ReTUR significantly influences prognosis. This study aimed to develop an interpretable machine learning model using CT radiomics to predict the risk of pathological upstaging following ReTUR in NMIBC patients. PATIENTS AND
methodsWe retrospectively analyzed 104 NMIBC patients who underwent ReTUR at the Second Affiliated Hospital of Nanchang University from March 2019 to July 2022. Data were split 7:3 into training and internal validation sets. An external validation set included 40 patients from two other hospitals. Radiomic features were extracted from preoperative CT scans. Least Absolute Shrinkage and Selection Operator (LASSO) and multivariate logistic regression were used to identify predictors of pathological upstaging. Four machine learning models, including Extreme Gradient Boosting (XGBoost), Gradient Boosting Decision Tree (GBDT), Random Forest (RF), and Linear Discriminant Analysis (LDA), were constructed and evaluated using AUC, accuracy, precision, F1 score, calibration curves, and decision curve analysis (DCA). The best model was interpreted via SHapley Additive exPlanations (SHAP) to identify key predictive features.
resultsTumor grade (OR = 7.02, 95% CI: 1.17–42.21), tumor size (OR = 5.83, 95% CI: 1.21–28.15), and tumor number (OR = 6.83, 95% CI: 1.18–39.52) were independent risk factors. From 4,738 radiomic features, nine were selected. The XGBoost model outperformed others, with an AUC of 0.804 (95% CI: 0.756–0.862), accuracy of 77.4%, precision of 82.7%, and F1 score of 0.701 in internal validation. External validation confirmed its robustness. SHAP analysis highlighted Wavelet_LLH_firstorder_Maximum.1, Gradient_ngtdm_Complexity, and tumor grade as top predictors. The model showed good calibration and clinical utility on DCA.
conclusionAn interpretable CT radiomics-based machine learning model integrating clinical and imaging features was developed to accurately predict pathological upstaging risk after ReTUR in NMIBC patients. This tool may support clinical decision-making for individualized treatment after multicenter validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.